Metabasis Therapeutics (MBRX) Reports Q2 Loss of $0.34, Beats by 2c
Metabasis Therapeutics (Nasdaq: MBRX) reports a Q2 loss of $0.34, 2 cents better than the analyst estimate of ($0.36). Revenues for the quarter were $700K, versus the consensus of $1.24 million.
Related Categories
EarningsStocks Mentioned
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
